Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2006-03-30

AUTHORS

Alexander M Aiken, Philip C Hill, Annette Fox, Keith PWJ McAdam, Dolly Jackson-Sillah, Moses D Lugos, Simon A Donkor, Richard A Adegbola, Roger H Brookes

ABSTRACT

BACKGROUND: New tools are required to improve tuberculosis (TB) diagnosis and treatment, including enhanced ability to compare new treatment strategies. The ELISPOT assay uses Mycobacterium tuberculosis-specific antigens to produce a precise quantitative readout of the immune response to pathogen. We hypothesized that TB patients in The Gambia would have reduced ELISPOT counts after successful treatment. METHODS: We recruited Gambian adults with sputum smear and culture positive tuberculosis for ELISPOT assay and HIV test, and followed them up one year later to repeat testing and document treatment outcome. We used ESAT-6, CFP-10 and Purified Protein Derivative (PPD) as stimulatory antigens. We confirmed the reliability of our assay in 23 volunteers through 2 tests one week apart, comparing within and between subject variation. RESULTS: We performed an ELISPOT test at diagnosis and 12 months later in 89 patients. At recruitment, 70/85 HIV-negative patients (82%) were ESAT-6 or CFP-10 (EC) ELISPOT positive, 77 (90%) were PPD ELISPOT positive. Eighty-two cases (96%) successfully completed treatment: 44 (55%; p < 0.001) were EC ELISPOT negative at 12 months, 17 (21%; p = 0.051) were PPD ELISPOT negative. Sixty (73%) cured cases had a CFP-10 ELISPOT count decrease, 64 (78%) had an ESAT-6 ELISPOT count decrease, 58 (70%) had a PPD ELISPOT count decrease. There was a mean decline of 25, 44 and 47 SFU/2 x 105 cells for CFP-10, ESAT-6 and PPD respectively (p < 0.001 for all). Three of 4 HIV positive patients were cured, all 3 underwent ELISPOT reversion; all 4 not cured subjects (3 HIV-negative, 1 HIV positive) were ESAT-6, CFP-10 and PPD ELISPOT positive at 12 months. CONCLUSION: Successful tuberculosis treatment is accompanied by a significant reduction in the M. tuberculosis-specific antigen ELISPOT count. The ELISPOT has potential as a proxy measure of TB treatment outcome. Further investigation into the decay kinetics of T-cells with treatment is warranted. More... »

PAGES

66-66

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2334-6-66

DOI

http://dx.doi.org/10.1186/1471-2334-6-66

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037367872

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16573826


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Bacterial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme-Linked Immunosorbent Assay", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gambia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-gamma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mycobacterium tuberculosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sputum", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Lymphocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tuberculosis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia", 
          "id": "http://www.grid.ac/institutes/grid.415063.5", 
          "name": [
            "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aiken", 
        "givenName": "Alexander M", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia", 
          "id": "http://www.grid.ac/institutes/grid.415063.5", 
          "name": [
            "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hill", 
        "givenName": "Philip C", 
        "id": "sg:person.01061416713.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061416713.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia", 
          "id": "http://www.grid.ac/institutes/grid.415063.5", 
          "name": [
            "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fox", 
        "givenName": "Annette", 
        "id": "sg:person.01054133437.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054133437.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia", 
          "id": "http://www.grid.ac/institutes/grid.415063.5", 
          "name": [
            "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McAdam", 
        "givenName": "Keith PWJ", 
        "id": "sg:person.010637717514.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010637717514.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia", 
          "id": "http://www.grid.ac/institutes/grid.415063.5", 
          "name": [
            "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jackson-Sillah", 
        "givenName": "Dolly", 
        "id": "sg:person.0704653674.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704653674.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia", 
          "id": "http://www.grid.ac/institutes/grid.415063.5", 
          "name": [
            "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lugos", 
        "givenName": "Moses D", 
        "id": "sg:person.01013503722.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013503722.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia", 
          "id": "http://www.grid.ac/institutes/grid.415063.5", 
          "name": [
            "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Donkor", 
        "givenName": "Simon A", 
        "id": "sg:person.015661626027.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015661626027.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia", 
          "id": "http://www.grid.ac/institutes/grid.415063.5", 
          "name": [
            "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adegbola", 
        "givenName": "Richard A", 
        "id": "sg:person.0674447752.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674447752.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia", 
          "id": "http://www.grid.ac/institutes/grid.415063.5", 
          "name": [
            "Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brookes", 
        "givenName": "Roger H", 
        "id": "sg:person.01322544210.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322544210.31"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2006-03-30", 
    "datePublishedReg": "2006-03-30", 
    "description": "BACKGROUND: New tools are required to improve tuberculosis (TB) diagnosis and treatment, including enhanced ability to compare new treatment strategies. The ELISPOT assay uses Mycobacterium tuberculosis-specific antigens to produce a precise quantitative readout of the immune response to pathogen. We hypothesized that TB patients in The Gambia would have reduced ELISPOT counts after successful treatment.\nMETHODS: We recruited Gambian adults with sputum smear and culture positive tuberculosis for ELISPOT assay and HIV test, and followed them up one year later to repeat testing and document treatment outcome. We used ESAT-6, CFP-10 and Purified Protein Derivative (PPD) as stimulatory antigens. We confirmed the reliability of our assay in 23 volunteers through 2 tests one week apart, comparing within and between subject variation.\nRESULTS: We performed an ELISPOT test at diagnosis and 12 months later in 89 patients. At recruitment, 70/85 HIV-negative patients (82%) were ESAT-6 or CFP-10 (EC) ELISPOT positive, 77 (90%) were PPD ELISPOT positive. Eighty-two cases (96%) successfully completed treatment: 44 (55%; p < 0.001) were EC ELISPOT negative at 12 months, 17 (21%; p = 0.051) were PPD ELISPOT negative. Sixty (73%) cured cases had a CFP-10 ELISPOT count decrease, 64 (78%) had an ESAT-6 ELISPOT count decrease, 58 (70%) had a PPD ELISPOT count decrease. There was a mean decline of 25, 44 and 47 SFU/2 x 105 cells for CFP-10, ESAT-6 and PPD respectively (p < 0.001 for all). Three of 4 HIV positive patients were cured, all 3 underwent ELISPOT reversion; all 4 not cured subjects (3 HIV-negative, 1 HIV positive) were ESAT-6, CFP-10 and PPD ELISPOT positive at 12 months.\nCONCLUSION: Successful tuberculosis treatment is accompanied by a significant reduction in the M. tuberculosis-specific antigen ELISPOT count. The ELISPOT has potential as a proxy measure of TB treatment outcome. Further investigation into the decay kinetics of T-cells with treatment is warranted.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1471-2334-6-66", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2753356", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1024946", 
        "issn": [
          "1471-2334"
        ], 
        "name": "BMC Infectious Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "Purified Protein Derivative", 
      "count decrease", 
      "ELISPOT test", 
      "treatment outcomes", 
      "ELISPOT counts", 
      "Mycobacterium tuberculosis-specific antigens", 
      "HIV-negative patients", 
      "tuberculosis-specific antigens", 
      "successful tuberculosis treatment", 
      "TB treatment outcomes", 
      "HIV positive patients", 
      "new treatment strategies", 
      "EC ELISPOT", 
      "TB patients", 
      "positive tuberculosis", 
      "positive patients", 
      "Gambian adults", 
      "HIV test", 
      "tuberculosis cases", 
      "ELISPOT assay", 
      "tuberculosis treatment", 
      "successful treatment", 
      "sputum smears", 
      "stimulatory antigens", 
      "treatment strategies", 
      "immune response", 
      "ELISPOT", 
      "tuberculosis diagnosis", 
      "mean decline", 
      "protein derivative", 
      "patients", 
      "ESAT-6", 
      "test one week", 
      "months", 
      "treatment", 
      "significant reduction", 
      "further investigation", 
      "diagnosis", 
      "antigen", 
      "outcomes", 
      "subject variation", 
      "proxy measure", 
      "counts", 
      "enhanced ability", 
      "cells", 
      "decrease", 
      "tuberculosis", 
      "weeks", 
      "smears", 
      "cases", 
      "volunteers", 
      "adults", 
      "test", 
      "subjects", 
      "Gambia", 
      "assays", 
      "pathogens", 
      "years", 
      "reversion", 
      "response", 
      "recruitment", 
      "decline", 
      "quantitative readout", 
      "testing", 
      "new tool", 
      "reduction", 
      "measures", 
      "sixties", 
      "ability", 
      "strategies", 
      "investigation", 
      "tool", 
      "reliability", 
      "derivatives", 
      "kinetics", 
      "variation", 
      "decay kinetics", 
      "readout", 
      "precise quantitative readout", 
      "document treatment outcome", 
      "one week", 
      "PPD ELISPOT", 
      "ELISPOT count decrease", 
      "ESAT-6 ELISPOT count decrease", 
      "PPD ELISPOT count decrease", 
      "SFU/2 x 105 cells", 
      "x 105 cells", 
      "ELISPOT reversion", 
      "tuberculosis-specific antigen ELISPOT count", 
      "antigen ELISPOT count", 
      "Gambian tuberculosis cases"
    ], 
    "name": "Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases", 
    "pagination": "66-66", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037367872"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2334-6-66"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16573826"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2334-6-66", 
      "https://app.dimensions.ai/details/publication/pub.1037367872"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_421.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1471-2334-6-66"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-6-66'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-6-66'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-6-66'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-6-66'


 

This table displays all metadata directly associated to this object as RDF triples.

273 TRIPLES      21 PREDICATES      133 URIs      125 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2334-6-66 schema:about N09855b9a993b4217b5b32e955eaf611d
2 N1b006dfa9ff541f7bce935a905a6b827
3 N2b912ef0e7954ef1afcd2437ce3767d6
4 N31b78fa3212342a49a82fe55b36f0c99
5 N3575d41913214e2fbcde48ed70bd565a
6 N374c29d25ad74927b043b1bb6a01c1cd
7 N3960551ecc8948c8b9ac0cee0d6016f0
8 N6013f140edb84e2bbfab0d21bc545c97
9 N6a04de0386a94a81b18cccc23a57f557
10 N6b4650d5e5144851b59006ce858b5ea1
11 N7b02865e9b9b4b24927e40186661589f
12 N7d9fa4a1914d4dc084866abccdc65343
13 N9a3312036ae84e60bec3fdd886709ee4
14 N9c91d0db5fde4909aee8661d031c813b
15 N9d248e885a9c4689a4e22291f2160714
16 Nb63a7a6cdb5c46b6b164bf6f5d243bbc
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N6ca5de1e60084e09bc54877feb6f013c
20 schema:datePublished 2006-03-30
21 schema:datePublishedReg 2006-03-30
22 schema:description BACKGROUND: New tools are required to improve tuberculosis (TB) diagnosis and treatment, including enhanced ability to compare new treatment strategies. The ELISPOT assay uses Mycobacterium tuberculosis-specific antigens to produce a precise quantitative readout of the immune response to pathogen. We hypothesized that TB patients in The Gambia would have reduced ELISPOT counts after successful treatment. METHODS: We recruited Gambian adults with sputum smear and culture positive tuberculosis for ELISPOT assay and HIV test, and followed them up one year later to repeat testing and document treatment outcome. We used ESAT-6, CFP-10 and Purified Protein Derivative (PPD) as stimulatory antigens. We confirmed the reliability of our assay in 23 volunteers through 2 tests one week apart, comparing within and between subject variation. RESULTS: We performed an ELISPOT test at diagnosis and 12 months later in 89 patients. At recruitment, 70/85 HIV-negative patients (82%) were ESAT-6 or CFP-10 (EC) ELISPOT positive, 77 (90%) were PPD ELISPOT positive. Eighty-two cases (96%) successfully completed treatment: 44 (55%; p < 0.001) were EC ELISPOT negative at 12 months, 17 (21%; p = 0.051) were PPD ELISPOT negative. Sixty (73%) cured cases had a CFP-10 ELISPOT count decrease, 64 (78%) had an ESAT-6 ELISPOT count decrease, 58 (70%) had a PPD ELISPOT count decrease. There was a mean decline of 25, 44 and 47 SFU/2 x 105 cells for CFP-10, ESAT-6 and PPD respectively (p < 0.001 for all). Three of 4 HIV positive patients were cured, all 3 underwent ELISPOT reversion; all 4 not cured subjects (3 HIV-negative, 1 HIV positive) were ESAT-6, CFP-10 and PPD ELISPOT positive at 12 months. CONCLUSION: Successful tuberculosis treatment is accompanied by a significant reduction in the M. tuberculosis-specific antigen ELISPOT count. The ELISPOT has potential as a proxy measure of TB treatment outcome. Further investigation into the decay kinetics of T-cells with treatment is warranted.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf N2d6bab51a3504adbb6c9f515a65df400
27 N6a891942231c4cfc8f846deb13b84e05
28 sg:journal.1024946
29 schema:keywords EC ELISPOT
30 ELISPOT
31 ELISPOT assay
32 ELISPOT count decrease
33 ELISPOT counts
34 ELISPOT reversion
35 ELISPOT test
36 ESAT-6
37 ESAT-6 ELISPOT count decrease
38 Gambia
39 Gambian adults
40 Gambian tuberculosis cases
41 HIV positive patients
42 HIV test
43 HIV-negative patients
44 Mycobacterium tuberculosis-specific antigens
45 PPD ELISPOT
46 PPD ELISPOT count decrease
47 Purified Protein Derivative
48 SFU/2 x 105 cells
49 TB patients
50 TB treatment outcomes
51 ability
52 adults
53 antigen
54 antigen ELISPOT count
55 assays
56 cases
57 cells
58 count decrease
59 counts
60 decay kinetics
61 decline
62 decrease
63 derivatives
64 diagnosis
65 document treatment outcome
66 enhanced ability
67 further investigation
68 immune response
69 investigation
70 kinetics
71 mean decline
72 measures
73 months
74 new tool
75 new treatment strategies
76 one week
77 outcomes
78 pathogens
79 patients
80 positive patients
81 positive tuberculosis
82 precise quantitative readout
83 protein derivative
84 proxy measure
85 quantitative readout
86 readout
87 recruitment
88 reduction
89 reliability
90 response
91 reversion
92 significant reduction
93 sixties
94 smears
95 sputum smears
96 stimulatory antigens
97 strategies
98 subject variation
99 subjects
100 successful treatment
101 successful tuberculosis treatment
102 test
103 test one week
104 testing
105 tool
106 treatment
107 treatment outcomes
108 treatment strategies
109 tuberculosis
110 tuberculosis cases
111 tuberculosis diagnosis
112 tuberculosis treatment
113 tuberculosis-specific antigen ELISPOT count
114 tuberculosis-specific antigens
115 variation
116 volunteers
117 weeks
118 x 105 cells
119 years
120 schema:name Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases
121 schema:pagination 66-66
122 schema:productId N4e4d32b7628049b08259fb67722c1c3c
123 Nb3aa3d08dd094ce1b34027c838885ac2
124 Nf399febe79ef4633bb39f513725e1c7b
125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037367872
126 https://doi.org/10.1186/1471-2334-6-66
127 schema:sdDatePublished 2021-12-01T19:18
128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
129 schema:sdPublisher N6279fb14fc4443f1a6bc310b457f9afe
130 schema:url https://doi.org/10.1186/1471-2334-6-66
131 sgo:license sg:explorer/license/
132 sgo:sdDataset articles
133 rdf:type schema:ScholarlyArticle
134 N09855b9a993b4217b5b32e955eaf611d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Aged, 80 and over
136 rdf:type schema:DefinedTerm
137 N140854b9a6f9412f907019fbc0eabfa5 rdf:first sg:person.0674447752.92
138 rdf:rest Nac98f7ad7f8e408e8f122d1564648961
139 N1b006dfa9ff541f7bce935a905a6b827 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Adult
141 rdf:type schema:DefinedTerm
142 N2b912ef0e7954ef1afcd2437ce3767d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Middle Aged
144 rdf:type schema:DefinedTerm
145 N2d6bab51a3504adbb6c9f515a65df400 schema:issueNumber 1
146 rdf:type schema:PublicationIssue
147 N31b78fa3212342a49a82fe55b36f0c99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Interferon-gamma
149 rdf:type schema:DefinedTerm
150 N3575d41913214e2fbcde48ed70bd565a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Female
152 rdf:type schema:DefinedTerm
153 N374c29d25ad74927b043b1bb6a01c1cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Enzyme-Linked Immunosorbent Assay
155 rdf:type schema:DefinedTerm
156 N3960551ecc8948c8b9ac0cee0d6016f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Gambia
158 rdf:type schema:DefinedTerm
159 N46c88cc64ae84e008fc41a4d1c8808cf rdf:first sg:person.010637717514.91
160 rdf:rest Nee2affd21a6241edbd88209da243d942
161 N4e4d32b7628049b08259fb67722c1c3c schema:name doi
162 schema:value 10.1186/1471-2334-6-66
163 rdf:type schema:PropertyValue
164 N6013f140edb84e2bbfab0d21bc545c97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Antigens, Bacterial
166 rdf:type schema:DefinedTerm
167 N6279fb14fc4443f1a6bc310b457f9afe schema:name Springer Nature - SN SciGraph project
168 rdf:type schema:Organization
169 N6a04de0386a94a81b18cccc23a57f557 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Aged
171 rdf:type schema:DefinedTerm
172 N6a891942231c4cfc8f846deb13b84e05 schema:volumeNumber 6
173 rdf:type schema:PublicationVolume
174 N6b4650d5e5144851b59006ce858b5ea1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Mycobacterium tuberculosis
176 rdf:type schema:DefinedTerm
177 N6ca5de1e60084e09bc54877feb6f013c rdf:first N73a143213c0248bd9b9406267fbb4020
178 rdf:rest Na6759725c2e148d9982c24e3a497e668
179 N72eccdd2d65a4a2faa19912c938ca637 rdf:first sg:person.01013503722.79
180 rdf:rest Nac001de9f7374b2a961450f31b2f1dab
181 N73a143213c0248bd9b9406267fbb4020 schema:affiliation grid-institutes:grid.415063.5
182 schema:familyName Aiken
183 schema:givenName Alexander M
184 rdf:type schema:Person
185 N7b02865e9b9b4b24927e40186661589f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name T-Lymphocytes
187 rdf:type schema:DefinedTerm
188 N7d9fa4a1914d4dc084866abccdc65343 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Adolescent
190 rdf:type schema:DefinedTerm
191 N8364f92f2f844117871faab357bc4f6c rdf:first sg:person.01054133437.41
192 rdf:rest N46c88cc64ae84e008fc41a4d1c8808cf
193 N9a3312036ae84e60bec3fdd886709ee4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Sputum
195 rdf:type schema:DefinedTerm
196 N9c91d0db5fde4909aee8661d031c813b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Male
198 rdf:type schema:DefinedTerm
199 N9d248e885a9c4689a4e22291f2160714 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Humans
201 rdf:type schema:DefinedTerm
202 Na6759725c2e148d9982c24e3a497e668 rdf:first sg:person.01061416713.85
203 rdf:rest N8364f92f2f844117871faab357bc4f6c
204 Nac001de9f7374b2a961450f31b2f1dab rdf:first sg:person.015661626027.17
205 rdf:rest N140854b9a6f9412f907019fbc0eabfa5
206 Nac98f7ad7f8e408e8f122d1564648961 rdf:first sg:person.01322544210.31
207 rdf:rest rdf:nil
208 Nb3aa3d08dd094ce1b34027c838885ac2 schema:name dimensions_id
209 schema:value pub.1037367872
210 rdf:type schema:PropertyValue
211 Nb63a7a6cdb5c46b6b164bf6f5d243bbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Tuberculosis
213 rdf:type schema:DefinedTerm
214 Nee2affd21a6241edbd88209da243d942 rdf:first sg:person.0704653674.60
215 rdf:rest N72eccdd2d65a4a2faa19912c938ca637
216 Nf399febe79ef4633bb39f513725e1c7b schema:name pubmed_id
217 schema:value 16573826
218 rdf:type schema:PropertyValue
219 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
220 schema:name Medical and Health Sciences
221 rdf:type schema:DefinedTerm
222 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
223 schema:name Clinical Sciences
224 rdf:type schema:DefinedTerm
225 sg:grant.2753356 http://pending.schema.org/fundedItem sg:pub.10.1186/1471-2334-6-66
226 rdf:type schema:MonetaryGrant
227 sg:journal.1024946 schema:issn 1471-2334
228 schema:name BMC Infectious Diseases
229 schema:publisher Springer Nature
230 rdf:type schema:Periodical
231 sg:person.01013503722.79 schema:affiliation grid-institutes:grid.415063.5
232 schema:familyName Lugos
233 schema:givenName Moses D
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013503722.79
235 rdf:type schema:Person
236 sg:person.01054133437.41 schema:affiliation grid-institutes:grid.415063.5
237 schema:familyName Fox
238 schema:givenName Annette
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054133437.41
240 rdf:type schema:Person
241 sg:person.01061416713.85 schema:affiliation grid-institutes:grid.415063.5
242 schema:familyName Hill
243 schema:givenName Philip C
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061416713.85
245 rdf:type schema:Person
246 sg:person.010637717514.91 schema:affiliation grid-institutes:grid.415063.5
247 schema:familyName McAdam
248 schema:givenName Keith PWJ
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010637717514.91
250 rdf:type schema:Person
251 sg:person.01322544210.31 schema:affiliation grid-institutes:grid.415063.5
252 schema:familyName Brookes
253 schema:givenName Roger H
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322544210.31
255 rdf:type schema:Person
256 sg:person.015661626027.17 schema:affiliation grid-institutes:grid.415063.5
257 schema:familyName Donkor
258 schema:givenName Simon A
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015661626027.17
260 rdf:type schema:Person
261 sg:person.0674447752.92 schema:affiliation grid-institutes:grid.415063.5
262 schema:familyName Adegbola
263 schema:givenName Richard A
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674447752.92
265 rdf:type schema:Person
266 sg:person.0704653674.60 schema:affiliation grid-institutes:grid.415063.5
267 schema:familyName Jackson-Sillah
268 schema:givenName Dolly
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704653674.60
270 rdf:type schema:Person
271 grid-institutes:grid.415063.5 schema:alternateName Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia
272 schema:name Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia
273 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...